MedTrace Logo

Lipidome and Microbiome Profile of the Eye in Rosacea

NCT03655197 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-09-18

No results posted yet for this study

Summary

The question that the investigators aim to address in this proposal is how the local lipid mediator profiles of ceramides and eicosanoids are altered in cutaneous and ocular rosacea and how antibiotics alter the lipidome. The investigators also seek to understand how the microbiome is changed in those with and without rosacea, and how the microbiome is altered in those with rosacea. Understanding how the lipidome is modulated in rosacea with antibiotic treatment will serve as the first step in targeting therapies toward directly altering the lipidome to reduce inflammation and ultimately reduce the use of antibiotics.

Conditions

  • Rosacea
  • Ocular Rosacea
  • Cutaneous Rosacea

Interventions

DRUG

Doxycycline

For those participating in the Doxycycline intervention, they will take 100 mg twice daily for 1 month.

Sponsors & Collaborators

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Raja Sivamani, MD, MS · UC Davis, Department of Dermatology

  • Mark Mannis, MD · UC Davis, Department of Ophthalmology

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-02
Primary Completion
2021-06-30
Completion
2021-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03655197 on ClinicalTrials.gov